News Center
News Center
The pharmaceutical machinery market is becoming more rational, giving rise to multifunctional coating machines.

The pharmaceutical machinery market is becoming more rational, giving rise to multifunctional coating machines.

In recent years, driven by the improving domestic environment and supportive national policies, China’s pharmaceutical industry has experienced rapid growth, leading to the widespread adoption of multifunctional coating machines. Meanwhile, the development and application of novel drug formulations and advanced drug-release technologies have placed increasingly stringent demands on coating equipment. According to reports, the multifunctional coating machine is a cutting-edge piece of equipment that boasts enhanced production capacity while offering simplified operation. It is particularly well-suited for the pharmaceutical, food, and health-care industries, where it is used to apply sugar coatings, polish tablets and pellets, and produce round pellets through tumbling. In addition, the machine is equipped with a forced-air heating system, ensuring that coated tablets exhibit a bright, lustrous finish; it also supports continuous coating operations. The coating pan is constructed from stainless steel, fully complying with GMP manufacturing standards. The multifunctional coating machine incorporates a large-coat–small-material mechanical configuration. Through internal mechanical adjustments, small batches of plain tablets can be coated within the larger pan without wasting excipients, thereby significantly expanding its range of applications. Its automated feeding and discharging systems effectively prevent cross-contamination, while providing convenient and highly efficient material handling. Moreover, the streamlined design of the flow-guiding plates minimizes the adhesion of excipients to their surfaces, further reducing excipient consumption and enhancing product quality. Chinese coating-machine manufacturers are continuously investing in technological R&D and product innovation, resulting in ongoing improvements and upgrades that make their equipment more rational and user-friendly. In summary, technological innovation and equipment modernization are enduring priorities for pharmaceutical companies; the introduction of advanced new products heralds the potential arrival of a second GMP era. Looking ahead, the pharmaceutical machinery market will become increasingly rational: as long as manufacturers persist in upgrading their products and prioritizing technological advancement, they will continue to earn customer recognition.

15

2021/07

The API industry has entered a new stage of development, presenting both opportunities and challenges for pharmaceutical equipment manufacturers.

The API industry has entered a new stage of development, presenting both opportunities and challenges for pharmaceutical equipment manufacturers.

Active pharmaceutical ingredients, or APIs, are substances produced through chemical synthesis, plant extraction, or biotechnology; however, they cannot be administered directly to patients and typically require the addition of excipients and further processing before they can be formulated into finished medicinal products. China has now become one of the world’s major API markets. In recent years, with the accelerated reform of China’s healthcare policies, the annual number of newly registered DMFs has steadily increased, and the scale of API exports has also begun to grow rapidly. According to data from the National Bureau of Statistics, in 2019 China’s output of chemical APIs reached 2.769 million tonnes, up 20.2% year on year; in 2020, output stood at 2.734 million tonnes, a year-on-year increase of 2.7%. Furthermore, the “In-depth Research Report on China’s API Industry and Investment Prospect Forecast for 2020–2024” indicates that in 2019 the size of China’s API market had already reached RMB 257.929 billion, representing a year-on-year growth of 6.4%. Industry analysts believe that, over the medium to long term, as API production capacity gradually shifts toward the Asia-Pacific region and demand for APIs rises under centralized procurement, China’s API market will continue to expand. However, given the current industry landscape—characterized by fragmentation, disorder, cutthroat price competition, severe resource waste, and overcapacity—industry experts anticipate that the domestic API sector will soon enter a period of transformation and usher in a new phase of development. During this new phase, the industry expects stricter regulatory requirements and greater emphasis on cost control across the entire API value chain. It is well known that API manufacturing often generates by-products such as wastewater, exhaust gases, and solid waste. In recent years, as the Chinese government has placed increasing emphasis on environmental protection, higher environmental standards have been imposed on the API industry. For example, the Environmental Protection Tax Law came into effect in 2018, and the subsequent introduction of the environmental tax along with intensified environmental inspections and follow-up reviews have further increased pressure on API manufacturers; nearly 70% of API producers have been forced to suspend operations due to the high costs of meeting these environmental requirements. Moreover, the issuance in 2019 of the Guiding Opinions on Promoting Green Development of the API Industry has accelerated the elimination of outdated production capacity and facilitated large-scale industry consolidation. Against this backdrop, industry insiders believe that environmentally friendly, green-process APIs will become a key priority for national industrial policy support. Consequently, the API equipment manufacturing sector is expected to see growing opportunities. In particular, low-cost, high-efficiency, energy-saving, and eco-friendly pharmaceutical equipment is likely to set new trends in API production. According to reports, many domestic API equipment manufacturers are already stepping up their efforts in the area of environmental protection and energy efficiency. For instance, one drying equipment manufacturer has continuously increased its R&D investment to develop environmentally friendly and energy-efficient API production equipment. The company has established a dedicated environmental protection subsidiary and a corresponding engineering testing center, and has defined core design elements for energy-saving, consumption-reducing, and environmentally friendly products, actively pursuing the R&D and production of green equipment. As a result, it has gradually achieved both economic and social benefits. Other companies are integrating new technologies into the R&D and production of API equipment. For example, one firm has developed a liquid-nitrogen freeze-dryer that uses liquid nitrogen as a cooling source; a novel sterilization process that leverages existing vacuum systems to deliver gaseous water into the freeze-dryer’s piping for hydrogen-peroxide-based disinfection; and a fully automated solid–liquid separation solution that reduces energy and water consumption, labor requirements, and wastewater treatment costs while improving product recovery rates. Meanwhile, another company has assembled an experienced technical team specializing in heat-exchange equipment, with a focus on energy conservation and consumption reduction, committed to providing customers with effective solutions that lower costs and boost efficiency. Overall, these new technologies, new equipment, and new solutions from pharmaceutical equipment manufacturers are providing robust process support for high-quality API production. As the API industry enters a boom cycle, industry forecasts suggest that the related API equipment market will also experience growth. However, it is important to note that opportunities are often accompanied by challenges. Therefore, while seizing these opportunities, API equipment manufacturers must continually adapt to evolving market demands and requirements, innovate equipment and technologies, and refine equipment designs—in order to sustain the high-quality development of the innovative pharmaceutical API industry and deliver even better services to users.

10

2021/06

< 1 > proceed page
%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home